Journal Scans
High-Dose Carboplatin–Irinotecan–Temozolomide: Treatment Option for Neuroblastoma Resistant to Topotecan
High-Dose CIT Is Option to Topotecan-Resistant Neuroblastoma
BH Kushner, K Kramer, S Modak, N-KV Cheun
20110211
2011 Mar 11
Pediat Blood Cancer
High-Dose Carboplatin–Irinotecan–Temozolomide: Treatment Option for Neuroblastoma Resistant to Topotecan
Pediat Blood Cancer. 2011 Mar 11;56(3):403-408, BH Kushner, K Kramer, S Modak, N-KV Cheun
TAKE-HOME MESSAGE
Abstract
Abstract
Background: We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan. Patients and Methods: Forty-five patients received carboplatin (500 mg/m2/day, 2×)–irinotecan (50 mg/m2/day, 5×)–temozolomide (250 mg/m2/day, 5×) (HD-CIT). Only one course was planned. Patients with thrombocytopenia indicative of poor bone marrow (BM) reserve resulting from extensive prior therapy received peripheral...
